6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetic acid ethyl ester | 298704-30-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetic acid ethyl ester
• 英文别名: ethyl 2-(6-methyl-2-oxo-3-(phenethylamino)pyrazin-1(2H)-yl)acetate；Ethyl 2-[6-methyl-2-oxo-3-(2-phenylethylamino)pyrazin-1-yl]acetate
• CAS: 298704-30-0
• 化学式: C₁₇H₂₁N₃O₃
• 分子量: 315.372
• InChiKey: XQYGIARWHDIMRS-UHFFFAOYSA-N

物化性质

• 沸点：
  457.3±55.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetic acid ethyl ester 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 以81%的产率得到3-(2-phenethylamino)-6-methyl-1-methylenecarboxypyrazinone
  参考文献：
  名称：

  MASP-2 INHIBITORS AND METHODS OF USE

  摘要：

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物以及制造和使用这些化合物的方法。

  公开号：

  US20190367452A1
• 作为产物：
  描述：

  2-[(2-乙氧基-2-氧代乙基)氨基]-2-氧代乙酸乙酯 在 ruthenium trichloride 、 ammonium hydroxide 、 sodium bromate 、 三乙胺 、 三氟乙酸酐 、 三溴氧磷 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetic acid ethyl ester
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring p 3 -heterocycles with P 1 -monocyclic arginine surrogates

  摘要：

  Investigations on P-2-P-3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P-1-arginine derivatives. The design. synthesis. and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P-1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydrox amidines, (2) 2-aminopyrazines. and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00129-4

文献信息

• Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1526131A1

  公开（公告）日：2005-04-27

  The invention relates to compounds of formula (I) wherein A, B, X, R1, R2, G, R3, D and E have the meaning as cited in the description and the claims. Said compounds are useful as coagulants. The invention also relates to the production and use thereof as medicament.

  这项发明涉及式(I)的化合物 其中A、B、X、R1、R2、G、R3、D和E的含义如描述和权利要求中所述。所述化合物可用作凝血剂。该发明还涉及其作为药物的生产和使用。
• Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors
  申请人：Feurer Achim

  公开号：US20070099927A1

  公开（公告）日：2007-05-03

  The invention relates to compounds of formula (I) wherein A, B, X, R 1 , R 2 , G, R 3 , D and E have the meaning as cited in the description and the claims. Said compounds are useful as coagulants. The invention also relates to the production and use thereof as medicament.

  本发明涉及式(I)的化合物，其中A，B，X，R1，R2，G，R3，D和E的含义如描述和权利要求中所述。所述化合物可用作凝血剂。本发明还涉及其制备和用作药物的用途。
• Kilogram Scale Synthesis of the Pyrazinone Acetic Acid Core of an Orally Efficacious Thrombin Inhibitor
  作者：Fred J. Fleitz、Terry A. Lyle、Nan Zheng、Joseph D. Armstrong、R. P. Volante

  DOI：10.1080/00397910008086927

  日期：2000.9

  A multi-kilogram scale synthesis of the orally efficacious thrombin inhibitor 1 has been achieved via construction of the pyrazinone core from an unsymmetric oxalic diamide. Key features include judicious choice of reagents to minimize side products, a key ruthenium catalyzed oxidation, and development of reaction conditions amenable to large-scale synthesis.
• [EN] AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS<br/>[FR] AMINOALKYL-PYRAZINONES ET AMINOALKYL-PYRIDONES UTILISEES COMME INHIBITEURS DE THROMBINE
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005040137A1

  公开（公告）日：2005-05-06

  The invention relates to compounds of formula (1) wherein A, B, X, R<1>, R<2> , G, R< 3> , D and E have the meaning as cited in the description and the claims. Said compounds are useful as coagulants. The invention also relates to the production and use thereof as medicament.
• MASP-2 INHIBITORS AND METHODS OF USE
  申请人：Omeros Corporation

  公开号：US20190367452A1

  公开（公告）日：2019-12-05

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物以及制造和使用这些化合物的方法。